gip glp 1 tirzepatide Bumps and humps in the success of as the first GLP1 and receptor agonist The Tirzepatide Revolution: Is Dual

It produces more modest results than semaglutide or tirzepatide, typically around 8 percent body weight loss, but it was the first GLP-1 to receive FDA approval specifically for weight management and remains a viable option for patients who prefer a shorter-acting medication or who experience intolerable side effects on the more potent formulations

The most common side effects are gastrointestinal, including nausea, vomiting, diarrhoea, and abdominal discomfort, affecting up to 40% of patients initially

PubMed, Lundgren, Julie R., et al

294 , F414F422 (2008)

Relative validities of 3-day food records and the food frequency questionnaire

Dosing and Administration Start with 40,000 to 50,000 units of lipase per main meal and 10,000 to 25,000 units per snack